-
@ 41d1479a:9db71bc7
2025-05-24 13:07:48
nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgr8g2hyzql5lt4cxfjdj40hgtu6vydvsqvsesqy8canygcce3lwvyyapkyy
✍️ Jim Cramer discusses Abbott Laboratories (NYSE:ABT) and advises waiting for a lower entry due to a pending lawsuit, but the stock still delivered steady growth and is rebounding.
👉 Jim Cramer discussed Abbott Laboratories (NYSE:ABT) in May 2024
👉 Cramer advised waiting for a lower entry due to a pending lawsuit over baby formula
👉 The stock delivered steady growth, justifying Cramer's patient buy-on-dip approach
👉 Abbott Laboratories is rebounding as its diversified healthcare products and diagnostics tools see renewed investor interest
#JimCramer #business
nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgppz5w9eqygj2uju9nhxrkzs4vvun8j0ws39g4x75rutez22lxn3quvnneq